Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CHRS - Coherus Biosciences Inc
-0.22(-1.35%)9:00:00 PM 3/1/2021
Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Stock news

    3 Undervalued Biotechs Worth Adding to Your Watch List

    If you're like me, your investment watch list is overflowing with dozens of stocks and price alerts. Let's examine three biotechs trading at lower than average valuations and consider whether they might be worth putting on your watch list. Supernus Pharmaceuticals (NASDAQ: SUPN) makes drugs that treat disorders of the central nervous system, including epilepsy and Parkinson's disease.

    Coherus Management to Present at Upcoming Investor Conferences

    REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March. 41st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m. ETBarclays Global Healthcare Conference on Tuesday, March 9 at 1:15 p.m. ET The audio portion of the presentation will be available on the investors’ page of the Coherus BioSciences website at

    Coherus BioSciences Inc (CHRS) Q4 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter and Full Year 2020 Coherus BioSciences Conference Call. Today's call includes forward-looking statements regarding Coherus' current expectations.

    Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results

    - Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with first BLA filing expected this year - - Pipeline progress with CHS-1420 (adalimumab biosimilar) BLA accepted by FDA and FYB201 (ranibizumab biosimilar) BLA on track for mid-year filing - - Conference call and webcast today at 4:30 p.m. ET - REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Coheru...

    Coherus BioSciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 24, 2021 / Coherus BioSciences, Inc. (NASDAQ:CHRS) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 24, 2021 at 4:30 PM Eastern Time.

    Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th

    REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today announced that it will release fourth quarter and full year 2020 financial results after the market closes on Wednesday, February 24, 2021. The news release will be followed by an investor conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide ...

    Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

    REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (“FDA”) has accepted for review the 351(k) Biologics License Application (“BLA”) for CHS-1420, a Humira® (adalimumab) biosimilar product candidate, and has set a Biosimilar User Fee Act action date for December 2021. If approved, Coherus plans to launch the adalimumab biosimilar in the U.S. on or after July 1, 2...